 | |
 | |
| Names | |
|---|---|
| Preferred IUPAC name Methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.163.930 |
| EC Number |
|
| |
| |
| Properties | |
| C16H15F3N2O4 | |
| Molar mass | 356.301 g·mol−1 |
| Insoluble | |
| Solubility in other solvents | DMSO: 184 mg/mL;methanol andethanol: 63 mg/mL |
| Hazards | |
| GHS labelling: | |
 | |
| Warning | |
| H315,H319 | |
| P264,P280,P302+P352,P305+P351+P338,P321,P332+P313,P337+P313,P362 | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Bay K8644 is achemical compound that functions as anL-typecalcium channelagonist. Bay K8644 is used primarily as a biochemical research tool for this effect.[2] It is a structural analog ofnifedipine with positive inotropic activity, and as an aromatic it is highly lipid soluble.
Bay K8644 targetsL-typevoltage-gatedcalcium channels. It is the first positive inotropic agent shown to act specifically and directly on calcium channels.[3]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
